Page last updated: 2024-12-07
win 56291
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Win 56291: anti-rhinoviral drug; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 129539 |
CHEMBL ID | 143305 |
CHEBI ID | 47732 |
SCHEMBL ID | 9706281 |
MeSH ID | M0214382 |
Synonyms (23)
Synonym |
---|
5-[3-[2,6-dichloro-4-(4,5-dihydrooxazol-2-yl)phenoxy]propyl]-3-methyl-isoxazole |
5-{3-[2,6-dichloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]propyl}-3-methylisoxazole |
win 56291 |
win56291 |
5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methylisoxazole |
C06499 |
CHEMBL143305 , |
DB08728 |
5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole |
AC1L2VSF , |
5-[3-[2,6-dichloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]propyl]-3-methyl-1,2-oxazole |
win-56291 |
tvm6inf0bb , |
isoxazole, 5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl- |
107355-76-0 |
unii-tvm6inf0bb |
SCHEMBL9706281 |
chebi:47732 |
surecn9706281 |
DTXSID90148021 |
5-(3-(2,6-dichloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy)propyl)-3-methyl-1,2-oxazole |
Q27097913 |
PD004174 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID84889 | In vitro determined against HRV-1A in a plaque reduction assay | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Conformationally restricted analogues of disoxaril: a comparison of the activity against human rhinovirus types 14 and 1A. |
AID84736 | In vitro determined against HRV-14 in a plaque reduction assay | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Conformationally restricted analogues of disoxaril: a comparison of the activity against human rhinovirus types 14 and 1A. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (80.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.53
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |